Gene Mutations Predict Treatment Outcomes In Patients With Leukemia

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Genetics
Article Date: 11 Dec 2006 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Curing acute myeloid leukemia (AML), a rapidly progressing bone-marrow cancer, is possible, but only in about 20-30 percent of patients, depending on a number of prognostic factors. A team of German researchers who explored how treatment responses could vary based on the genetic makeup of leukemia cells are sharing their findings today during the 48th Annual Meeting of the American Society of Hematology (ASH(TM)).

"The treatment of leukemia has advanced remarkably over the last 20 years," said ASH President Kanti R. Rai, MD, of Long Island Jewish Medical Center and the Albert Einstein College of Medicine. "This study shows the possibility of refining therapy even further, so it's no longer a 'let's try this and see if it works' approach; instead, it offers the possibility to use molecular genetics approaches to improve treatment outcomes."

The researchers evaluated the leukemia cells of 872 AML patients ages 16- 60 with a normal genetic makeup, which occurs in about half of those with the disease. The most common genetic abnormalities found in the cancer cells were NPM1 mutations (in 53 percent of the samples), FLT3 mutations (in 31 percent), and CEBPA mutations (in 14 percent).

More than three-quarters of the patients experienced a complete remission after chemotherapy, and the NPM1 and CEBPA genes were most associated with success. Age (less than 48 years), the availability of a family member donor match for stem cell transplant, and the presence of the NPM1 and CEBPA mutations were predictors for both relapse-free survival and overall survival. Also of significance were internal tandem duplications on the FLT3 gene, known as FLT3-ITD. When paired with the NPM1 mutation, the FLT3-ITD mutation canceled the favorable impact of NPM1.

While in remission, 143 of the 171 patients who had a matched family donor underwent stem cell transplantation, a therapy strategy that offers one of the best chances of a cure, but also carries some of the greatest risks. Of those with the combination NPM1 positive and FLT3-ITD negative genotype, about 60 percent remained relapse-free after four years, whether or not they had a stem cell donor. Of those with other combinations of NPM1 and FLT3 mutations, the relapse-free rates dropped to 47 percent for those with a donor, and further still for those without a donor to 23 percent.

"In our study, specific genotypes emerged as important predictors of response to therapy and survival in AML patients," said Richard Schlenk, MD, head of the Clinical Trials Office of the German-Austrian AML Study Group (AMLSG) at the University of Ulm and lead study author. "The results may help doctors choose the best option from among the existing treatments for their patients and pave the way for new treatments aimed at unfavorable mutations."

The American Society of Hematology (http://www.hematology.org/) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

American Society of Hematology
http://www.hematology.org/